Efficacy and Safety of Ponatinib as a Second‑Line Treatment for Chronic‑Phase Chronic Myeloid Leukemia: Retrospective Study at Two Japanese Centers
Yoshimi Ishii(Yokohama City University Medical Center), Hideaki Nakajima(Yokohama City University), Kosuke Takayama(Yokohama City University Medical Center), Yuki Nakajima(Fujisawa City Hospital), Itaru Sato(Yokohama City University Medical Center), Takuya Miyazaki(Yokohama City University Medical Center), Shin Fujisawa(Yokohama City University Medical Center), Katsumichi Fujimaki(Fujisawa City Hospital), Takaaki Takeda(Fujisawa City Hospital), Yuto Hibino(Yokohama City University Medical Center), Kota Kawabata(Museum of Japanese Art Yamato Bunkakan)
Cited by 0
Related Papers
Nucleosides and nucleotides. 100. 2'-C-Cyano-2'-deoxy-1-.beta.-D-arabinofuranosylcytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside
|Journal of Medicinal Chemistry|1991|85
Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large <scp>B</scp>‐cell lymphoma in the rituximab era
|European Journal Of Haematology|2013|58
Heat stress results in incomplete C-to-U editing of maize chloroplast mRNAs and correlates with changes in chloroplast transcription rate
|Current Genetics|2001|53
Frequent p53 mutations at dipyrimidine sites in patients with pyothorax-associated lymphoma.
|PubMed|1998|51
Determination of the Disulfide Array in Sapecin, an Antibacterial Peptide of Sarcophaga peregrina (Flesh Fly)1
|The Journal of Biochemistry|1990|48